MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.310
+0.050
+3.97%
After Hours: 1.290 -0.02 -1.53% 17:06 01/24 EST
OPEN
1.200
PREV CLOSE
1.260
HIGH
1.310
LOW
1.130
VOLUME
4.47M
TURNOVER
--
52 WEEK HIGH
9.80
52 WEEK LOW
1.130
MARKET CAP
165.88M
P/E (TTM)
-1.5358
1D
5D
1M
3M
1Y
5Y
Atossa Therapeutics Announces Advancement To Part B Of Clinical Study Of AT-H201
Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE)
Benzinga · 6d ago
Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary DiseaseSEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a cli...
GlobeNewswire · 6d ago
BRIEF-Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
reuters.com · 12/22/2021 14:36
Atossa Genetics Reports Begins Enrollment Of Phase 2 Study Of Oral Endoxifen In Sweden
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current
Benzinga · 12/22/2021 14:31
Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur
Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-C...
PR Newswire · 12/16/2021 14:00
BRIEF-Atossa Therapeutics Completes Pre-IND Meeting With U.S. Food & Drug Administration
reuters.com · 12/06/2021 14:18
Atossa Therapeutics Completes Pre-IND Meeting With FDA On Z-Endoxifen
 Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and
Benzinga · 12/06/2021 14:17
Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 12/05/2021 11:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATOS. Analyze the recent business situations of Atossa Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATOS stock price target is 7.88 with a high estimate of 8.75 and a low estimate of 7.00.
High8.75
Average7.88
Low7.00
Current 1.310
EPS
Actual
Estimate
-0.70-0.53-0.35-0.18
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 98
Institutional Holdings: 32.94M
% Owned: 26.01%
Shares Outstanding: 126.62M
TypeInstitutionsShares
Increased
29
3.32M
New
20
2.87M
Decreased
25
7.43M
Sold Out
15
3.42M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
No Data
  • All
  • Financials
  • Insiders
More
About ATOS
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing medicines for breast cancer and Covid-19. Its Covid-19 drugs under development, including the AT-H201 program, is for severely ill patients on ventilators, and AT-301 COVID-19 is a nasal spray. Its nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier. AT-H201 program is to develop a therapy to improve lung and function like a chemical vaccine. It is also developing an oral formulation of Endoxifen to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy.

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.